Investment Opportunity

Ready to Dominate the Sexual Health and Wellness Market

Love Pharma | Listed on: CSE:LUV.CN

When it comes to women’s sexual health and sensitive issues like female sexual dysfunction, much of the pharma industry remains silent when it comes to possible solutions. However, by mixing innovative ideas with proven science, LOVE Pharma is set to provide new hope to an overlooked market growing at a rapid rate.

Why you should consider investing

  • 1. Well ahead of the competition:

    Love Pharma has a leading product with a unique upside in the under-represented area of Female Sexual Dysfunction.

  • 2. Products for a wide range of consumers:

    Love Pharma has a broad product range addressing a wide range of sexual wellness issues like fertility, desire, and male issues.

  • 3. Branching out into booming markets:

    Love Pharma has entered the booming market of sub-lingual strips, with plans to expand into other compounds in the future.

  • 4. Top quality management:

    Love Pharma’s management boasts a strong track record in forming companies and taking them to market with success.

  • 5. Solid foundations with global potential:

    Love Pharma has a strong position in the UK and Europe alongside a global potential.

  • 6. On the cusp of massive growth:

    Love Pharma has plenty of catalysts on the horizon, providing multiple opportunities for a valuation re-rate in line with larger peers.

All of the above translates into money-spinning potential for savvy investors. Access our full report to find out more about this exciting opportunity.

Find out more

What you need to know: tapping into a lucrative market


It’s estimated that 30-50% of women suffer from some form of Female Sexual Dysfunction (FSD) in the US alone. It’s a problem that needs addressing, but the right product has been missing – until now.

LOVE Pharma has developed a new treatment using unique ingredients that has the potential to fundamentally change the way FSD is treated.

The impact could be extremely profitable for the company and for early investors. Consider, for example, that the market for male sexual dysfunction products is already worth more than $2 billion, and that it’s thought the women’s market will become up to three times larger.

One report even estimates that it could grow by $3.1 billion between 2021 and 2025 alone.

With so much potential on offer, you can quickly see that LOVE Pharma couldn’t have timed its entry into the market any better.

But FSD is only one of several areas where LOVE Pharma is applying its innovative approach.

Providing a better treatment for FSD could have a huge impact on LOVE Pharma’s bottom line, but it’s not the only area where the company hopes to provide new hope. Its research into the causes of FSD—and the ways of treating it—has opened several other potentially profitable avenues for the company.


What you need to know: expanding product range


Though it remains laser focused on its strategic approach (rolling out its FSD treatment, Bloom, as a priority), at the same time the firm has in place a clear plan for how it will achieve long-term success and create several catalysts for growth in the weeks and months to come. 

For example, ToConceive is a product that takes advantage of the same ingredients as Bloom but in a way that looks to help couples who, because of lubrication problems, struggle to conceive in a natural way.

It’s another huge problem, with 75% of unexplained infertility cases thought to be due to such issues.

In addition to this, the company is also exploring ways the ingredients it uses—menthol and another called L-arginine—can specifically help increase sexual desire and performance in both men and women.

Indeed, it has already been found that, when used alongside CBD, THC and even psychedelics, the results are extremely positive.

There is little doubt the range of products LOVE Pharma is readying to rollout could have a huge impact on the sexual health and wellness markets—and, in turn, on its own valuation.


Company Info

When it comes to women’s sexual health and sensitive issues like female sexual dysfunction, much of the pharma industry remains silent when it comes to possible solutions. However, by mixing innovative ideas with proven science, LOVE Pharma is set to provide new hope to an overlooked market growing at a rapid rate.

Exchange / Symbol
Market Capitalization
$ (usd)
Current price
$ (usd)
Current mid price
$ (usd)
52 Week high price
$ (usd)
52 Week low price
$ (usd)

LOVE Pharma is an investment opportunity not to be missed. Access our full report to find out more about this exciting investment opportunity.



This communication is a paid advertisement. ValueTheMarkets is a trading name of Digitonic Ltd, and its owners, directors, officers, employees, affiliates, agents and assigns (collectively the “Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by Love Pharma Inc. to conduct investor awareness advertising and marketing and has paid the Publisher the equivalent of two hundred and sixteen thousand US dollars to produce and disseminate this and other similar articles and certain related banner advertisements. This compensation should be viewed as a major conflict with the Publisher’s ability to provide unbiased information or opinion.


Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to adversely affect share prices. Frequently companies profiled in our articles experience a large increase in share trading volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in share trading volume and share price may likely occur.


This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security.


Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position.

This communication is based on information generally available to the public and on an interview conducted with the company’s CEO, and does not contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher does not guarantee the accuracy or completeness of the information. Further, the information in this communication is not updated after publication and may become inaccurate or outdated. No reliance should be placed on the price or statistics information and no responsibility or liability is accepted for any error or inaccuracy. Any statements made should not be taken as an endorsement of analyst views.


The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser or a financial adviser. The Publisher has no access to non-public information about publicly traded companies. The information provided is general and impersonal, and is not tailored to any particular individual’s financial situation or investment objective(s) and this communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor or a personal recommendation to deal or invest in any particular company or product. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results.


This communication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. Statements in this communication that look forward in time, which include everything other than historical information, are based on assumptions and estimates by our content providers and involve risks and uncertainties that may affect the profiled company’s actual results of operations. These statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results and performance to differ materially from any future results or performance expressed or implied in the forward-looking statements. These risks, uncertainties and other factors include, among others: the success of the profiled company’s operations; the size and growth of the market for the company’s products and services; the company’s ability to fund its capital requirements in the near term and long term; pricing pressures; changes in business strategy, practices or customer relationships; general worldwide economic and business conditions; currency exchange and interest rate fluctuations; government, statutory, regulatory or administrative initiatives affecting the company’s business.


By reading this communication, you acknowledge that you have read and understand this disclaimer in full, and agree and accept that the Publisher provides no warranty in respect of the communication or the profiled company and accepts no liability whatsoever. You acknowledge and accept this disclaimer and that, to the greatest extent permitted under applicable law, you release and hold harmless the Publisher from any and all liability, damages, injury and adverse consequences arising from your use of this communication. You further agree that you are solely responsible for any financial outcome related to or arising from your investment decisions.


By reading this communication you agree that you have reviewed and fully agree to the Terms of Use found here and acknowledge that you have reviewed the Disclaimer found here If you do not agree to the Terms of Use, please contact to discontinue receiving future communications.


All trademarks used in this communication are the property of their respective trademark holders. Other than, the Publisher is not affiliated, connected, or associated with, and the communication is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks other than

AUTHORS: VALUETHEMARKETS and Digitonic Ltd and our affiliates are not responsible for the content or accuracy of this article. The information included in this article is based solely on information provided by the company or companies mentioned above. This article does not provide any financial advice and is not a recommendation to deal in any securities or product. News and research are not recommendations to deal, and investments may fall in value so that you could lose some or all of your investment. Past performance is not an indicator of future performance.

ValueTheMarkets do not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above piece. ValueTheMarkets have been paid to produce this piece by the company or companies mentioned above. Digitonic Ltd, the owner of, has been paid for the production of this piece by the company or companies mentioned above.